Director Stephen T. Zarrilli filed a Form 4 with the SEC on August 19, 2026, reporting the exercise of stock options and a same-day sale of Class A Common Stock in Globus Medical Inc on August 18, 2026.

Key Highlights

  • Option exercise: Zarrilli exercised stock options covering 25,000 shares of Class A Common Stock at an exercise price of $53.27 per share on August 18, 2026.
  • Share sale: All 25,000 acquired shares were sold on August 18, 2026, at a weighted average price of $87.0386 per share.
  • Sale price range: According to the filing, shares were sold in multiple transactions at prices ranging from $86.92 to $87.16, inclusive.
  • Resulting ownership: Following the transactions, Zarrilli's direct beneficial ownership of Class A Common Stock stands at 0 shares, according to the filing.
  • Options fully vested: The filing states the exercised options were granted on January 22, 2020, and are fully vested, with an expiration date of January 22, 2030.
  • Role: Zarrilli is identified as a Director of Globus Medical Inc (NYSE:GMED) in the filing.

Zarrilli's Option Exercise and Share Disposal at Globus Medical

According to the Form 4 filed August 19, 2026, Director Stephen T. Zarrilli of Globus Medical Inc (NYSE:GMED) completed a same-day exercise-and-sell transaction on August 18, 2026. The filing shows Zarrilli exercised stock options to acquire 25,000 shares of Class A Common Stock at an exercise price of $53.27 per share, designated with transaction code "M" in the filing.

The filing further discloses that Zarrilli simultaneously disposed of all 25,000 shares, designated with transaction code "S," at a weighted average price of $87.0386 per share. The filing notes these shares were sold across multiple transactions at prices ranging from $86.92 to $87.16, inclusive, and that Zarrilli undertakes to provide full information on individual transaction prices upon request from the issuer, any security holder, or SEC staff. The price of the derivative security at exercise is reported as $0.

The exercised options were originally granted on January 22, 2020, and are described in the filing as fully vested. Their expiration date is listed as January 22, 2030. Following both transactions, Zarrilli's direct beneficial ownership of Class A Common Stock in Globus Medical is reported as 0 shares. The Form 4 was signed by Kelly G. Huller as Attorney-in-Fact on August 19, 2026.

What Was Disclosed

Director Stephen T. Zarrilli disclosed the exercise of 25,000 fully vested stock options at $53.27 per share and the sale of all resulting shares at a weighted average price of $87.0386, leaving him with zero direct beneficial ownership of Globus Medical Class A Common Stock.